- Home
- ELDN vs APLT Comparison
ELDN vs APLT Comparison
Compare ELDN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- APLT
- Stock Information
- Founded
- ELDN 2004
- APLT 2016
- Country
- ELDN United States
- APLT United States
- Employees
- ELDN N/A
- APLT N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- APLT Health Care
- Exchange
- ELDN Nasdaq
- APLT Nasdaq
- Market Cap
- ELDN 202.4M
- APLT 178.6M
- IPO Year
- ELDN N/A
- APLT 2019
- Fundamental
- Price
- ELDN $2.73
- APLT $1.05
- Analyst Decision
- ELDN Strong Buy
- APLT Buy
- Analyst Count
- ELDN 2
- APLT 5
- Target Price
- ELDN $12.50
- APLT $4.13
- AVG Volume (30 Days)
- ELDN 998.5K
- APLT 11.7M
- Earning Date
- ELDN 11-11-2025
- APLT 11-06-2025
- Dividend Yield
- ELDN N/A
- APLT N/A
- EPS Growth
- ELDN N/A
- APLT N/A
- EPS
- ELDN 0.21
- APLT N/A
- Revenue
- ELDN N/A
- APLT $121,000.00
- Revenue This Year
- ELDN N/A
- APLT N/A
- Revenue Next Year
- ELDN N/A
- APLT $5,931.24
- P/E Ratio
- ELDN $12.80
- APLT N/A
- Revenue Growth
- ELDN N/A
- APLT N/A
- 52 Week Low
- ELDN $2.32
- APLT $0.30
- 52 Week High
- ELDN $5.54
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ELDN 54.22
- APLT 65.38
- Support Level
- ELDN $2.48
- APLT $0.56
- Resistance Level
- ELDN $2.71
- APLT $1.32
- Average True Range (ATR)
- ELDN 0.17
- APLT 0.17
- MACD
- ELDN 0.04
- APLT 0.05
- Stochastic Oscillator
- ELDN 60.95
- APLT 69.68
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.